Tilt Biotherapeutics

OverviewSuggest Edit

TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of  solid tumors as currently achieved for CD19+ hematological tumors.

TypePrivate
Founded2013
HQHelsinki, FI
Websitetiltbio.com

Recent NewsAll News

Latest Updates

Employees (est.) (May 2020)11

Tilt Biotherapeutics Office Locations

Tilt Biotherapeutics has an office in Helsinki
Helsinki, FI (HQ)
3 Haartmaninkatu
Show all (1)

Tilt Biotherapeutics Financials and Metrics

Summary Metrics

Founding Date

2013

Tilt Biotherapeutics total Funding

$10.6 m

Tilt Biotherapeutics latest funding size

$10.63 m

Time since last funding

3 years ago
Tilt Biotherapeutics's latest funding round in December 2016 was reported to be $10.6 m. In total, Tilt Biotherapeutics has raised $10.6 m
Show all financial metrics

Tilt Biotherapeutics Online and Social Media Presence

Embed Graph

Tilt Biotherapeutics Blogs

Springvest

Investment round organized by Springvest is now open (18.3.2020 – 17.4.2020), more information here.

Joao Santos

João Santos started as a Head of Cell Therapy in February 2020

Biotheus

TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123. Read the press release here.

LSX Investival

TILT´s CBO Aino Kalervo attended LSX Investival Showcase in London in November. Watch Aino´s presentation here.

ESMO IO Merit award

Head of Immunology Víctor Cervera-Car­ras­cón received Merit Award for ESMO Immuno-Oncology Congress 2019. Víctor will present his abstract “Increasing responses to T-cell therapies in solid tumours by the use of an engineered adenovirus coding for TNFa and IL-2” at the congress in Geneva in Decembe…

Business Now

TILT Biotherapeutics was featured in the September issue of Business Now. You can read the article in Finnish here.
Show more

Tilt Biotherapeutics Frequently Asked Questions

  • When was Tilt Biotherapeutics founded?

    Tilt Biotherapeutics was founded in 2013.

  • How many employees does Tilt Biotherapeutics have?

    Tilt Biotherapeutics has 11 employees.

  • Who are Tilt Biotherapeutics competitors?

    Competitors of Tilt Biotherapeutics include Clementia Pharmaceuticals, DBV Technologies and Synthace.

  • Where is Tilt Biotherapeutics headquarters?

    Tilt Biotherapeutics headquarters is located at 3 Haartmaninkatu, Helsinki.

  • Where are Tilt Biotherapeutics offices?

    Tilt Biotherapeutics has an office in Helsinki.

  • How many offices does Tilt Biotherapeutics have?

    Tilt Biotherapeutics has 1 office.